妇科恶性肿瘤的细胞减灭术——新的护理标准

Cytoreductive surgery for gynecologic malignancies--new standards of care.

作者信息

Suh-Burgmann Elizabeth, Powell C Bethan

机构信息

Gynecologic Oncology, The Permanente Medical Group, 1425 S. Main Street, Walnut Creek, CA 94596, USA.

出版信息

Surg Oncol Clin N Am. 2007 Jul;16(3):667-82, x-xi. doi: 10.1016/j.soc.2007.04.017.

DOI:10.1016/j.soc.2007.04.017

PMID:17606200

Abstract

Studies on cytoreductive surgery for advanced ovarian and primary peritoneal cancer have consistently shown a strong correlation between cytoreduction and survival, with the best survival observed in patients who have no visible residual disease after successful cytoreductive surgery. Recent data that intraperitoneal chemotherapy further improves survival after optimal cytoreduction adds to the potential benefit of such surgery. More recently, significant survival benefit from optimal cytoreduction has also been shown for patients with recurrent disease and for women with advanced endometrial carcinoma. The selection criteria for patients and critical aspects of the operative technique and timing of cytoreductive surgery are discussed.

摘要

关于晚期卵巢癌和原发性腹膜癌减瘤手术的研究一致表明，减瘤程度与生存率之间存在密切关联，成功进行减瘤手术后无可见残留病灶的患者生存率最佳。近期数据显示，腹腔内化疗在最佳减瘤术后能进一步提高生存率，这增加了此类手术的潜在益处。最近，对于复发性疾病患者和晚期子宫内膜癌女性患者，最佳减瘤手术也显示出显著的生存获益。本文讨论了患者的选择标准以及减瘤手术的关键手术技术和时机。